Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160206 · ClinicalTrials.gov registry record · Phase 2
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
A Phase 2 study of Recurrent Glioblastoma and Recurrent WHO Grade 4 Glioma, sponsored by Academic and Community Cancer Research United.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 3
- Study locations
NCT06160206 is a Phase 2 study of Recurrent Glioblastoma and Recurrent WHO Grade 4 Glioma that is actively recruiting participants, run by Academic and Community Cancer Research United. The registered enrollment target is 134 participants, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (100% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06160206, a Phase 2 study of Recurrent Glioblastoma and Recurrent WHO Grade 4 Glioma, is actively recruiting participants, sponsored by Academic and Community Cancer Research United.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving retifanlimab with bevacizumab and hypofractionated radiotherapy may work better in treating patients with recurrent glioblastoma than bevacizumab and hypofractionated radiotherapy alone.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- RADIATION Hypofractionated Radiation Therapy
- OTHER Electronic Health Record Review
- BIOLOGICAL Bevacizumab
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06160206
The ClinicalTrials.gov registry entry for NCT06160206 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (100% higher). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06160206 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06160206 about?
NCT06160206 is a clinical study titled "Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma". This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a t...
What is the current status of trial NCT06160206?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2024-10-02. Estimated completion is 2030-11-30.
What conditions does trial NCT06160206 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma.
What interventions are being tested in trial NCT06160206?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Hypofractionated Radiation Therapy (RADIATION), Electronic Health Record Review (OTHER), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06160206?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06160206 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
RECRUITING · Phase 2
-
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan in Recurrent Glioblastoma
RECRUITING · Phase 2
-
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.